Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments.

Biotechnology

Health Care

Therapeutics

AreteiaTx

Jorge Bartolome

Tom Denwood

Richard Fires, MBA, GPHR

Peter Wijngaard

Mark Kreston

Lex Kay

Kevin Wesbecker CPIM, CSCP

Herbert Vail

Christopher Courts, CPA

Calman Prussin, M.D.

The Leadership Team at Areteia Therapeutics is responsible for steering the company's strategic direction, overseeing drug development and clinical research, ensuring financial health, and maintaining operational excellence. Comprised of key executives across various functions, this team collaborates to advance Areteia's mission of improving asthma management and enhancing patient outcomes.

Leadership Team

Clinical Operations Team

Leadership Team

About

Team members

Other teams at AreteiaTx

Clinical Operations Team